person · Reporting owner

PAUL STEVEN M

Disclosed activity across 7 companies

Tapewire entity: 13211
SEC CIK: 0001237564

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	April 01, 2022	April 05, 2022
ELI LILLY & CoLLY · Entity 2794	EVP, Science and Technology	December 31, 2009	February 03, 2010
Rapport Therapeutics, Inc.RAPP · Entity 4394	Director	June 10, 2026	June 10, 2026
Sage Therapeutics, Inc.SAGE · Entity 77038	Director	January 03, 2024	January 04, 2024
Seaport Therapeutics, Inc.SPTX · Entity 4799	Director	April 30, 2026	May 04, 2026
Voyager Therapeutics, Inc.VYGR · Entity 6271	Director	June 03, 2021	June 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date April 01, 2022 · Filed April 05, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,000	Ending reported balance After 2022-04-01 transaction · row 11 11 source rows · reconciled sequence Row 1 · 2022-04-01 · Exercise / conversion · Acquired 15,000 · Balance 16,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 2 · 2022-04-01 · Sale · Disposed 253 · Balance 15,747 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2: Sale prices ranged from $165.91 to $166.41. Row 3 · 2022-04-01 · Sale · Disposed 4,948 · Balance 10,799 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3: Sale prices ranged from $168.30 to $169.30. Row 4 · 2022-04-01 · Sale · Disposed 4,872 · Balance 5,927 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4: Sale prices ranged from $169.32 to $170.28. Row 5 · 2022-04-01 · Sale · Disposed 1,235 · Balance 4,692 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5: Sale prices ranged from $170.70 to $171.63. Row 6 · 2022-04-01 · Sale · Disposed 1,434 · Balance 3,258 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6: Sale prices ranged from $171.75 to $172.73. Row 7 · 2022-04-01 · Sale · Disposed 642 · Balance 2,616 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7: Sale prices ranged from $172.83 to $173.37. Row 8 · 2022-04-01 · Sale · Disposed 90 · Balance 2,526 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 9 · 2022-04-01 · Sale · Disposed 526 · Balance 2,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8: Sale prices ranged from $176.04 to $176.88. Row 10 · 2022-04-01 · Sale · Disposed 825 · Balance 1,175 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9: Sale prices ranged from $177.12 to $178.00. Row 11 · 2022-04-01 · Sale · Disposed 175 · Balance 1,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.33 · Expires 2022-06-21	Direct	0	Reported balance After 2022-04-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-04-01 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

F2: Sale prices ranged from $165.91 to $166.41.

F3: Sale prices ranged from $168.30 to $169.30.

F4: Sale prices ranged from $169.32 to $170.28.

F5: Sale prices ranged from $170.70 to $171.63.

F6: Sale prices ranged from $171.75 to $172.73.

F7: Sale prices ranged from $172.83 to $173.37.

F8: Sale prices ranged from $176.04 to $176.88.

F9: Sale prices ranged from $177.12 to $178.00.

ELI LILLY & Co

Report date December 31, 2009 · Filed February 03, 2010

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,000	Ending reported balance After 2009-12-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2009-12-22 · Gift · Disposed 8,553 · Balance 33,854 Row 2 · 2009-12-23 · Gift · Disposed 28,854 · Balance 5,000
Common StockSEC Table I · non-derivative	Indirectby wife	37,407	Last balance in matching sequence After 2009-12-23 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2009-12-22 · Gift · Acquired 8,553 · Balance 8,553 F1: Reporting person disclaims beneficial ownership of these shares. Row 4 · 2009-12-23 · Gift · Acquired 28,854 · Balance 37,407 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirect401(k)	909	Reported balance Holding disclosure · report date 2009-12-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 909
Common StockSEC Table I · non-derivative	Indirectby daughter	579	Reported balance Holding disclosure · report date 2009-12-31 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 579 F1: Reporting person disclaims beneficial ownership of these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person disclaims beneficial ownership of these shares.

Rapport Therapeutics, Inc.

Report date June 10, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10	Direct	15,200	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Sage Therapeutics, Inc.

Report date January 03, 2024 · Filed January 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.67 · Expires 2034-01-03	Direct	3,971	Reported balance After 2024-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-01-03 · Grant · Acquired 3,971 · Balance 3,971 F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Seaport Therapeutics, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	863,031	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Conversion · Acquired 67,031 · Balance 863,031 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	12,258	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 12,258 · Balance 12,258 F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	991,192	Reported balance After 2026-04-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-30 · Grant · Acquired 991,192 · Balance 991,192
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-04 · Conversion · Disposed 210,526 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

Voyager Therapeutics, Inc.

Report date June 03, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2031-06-03	Direct	15,000	Reported balance After 2021-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Karuna Therapeutics, Inc.

Report date March 18, 2024 · Filed March 18, 2024

Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,550	Reported balance After 2024-03-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-18 · Disposition to issuer · Disposed 2,046 · Balance 8,550 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-03-18 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-03-18 · Disposition to issuer · Disposed 8,550 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectSteve M. Paul Family 2021 Delaware Trust	0	Reported balance After 2024-03-18 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-03-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectThe Steven M Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2024-03-18 · Disposition to issuer · Disposed 33,882 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	IndirectSteven M. Paul Family 2024 Trust	0	Reported balance After 2024-03-18 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E. Paul GRAT III	0	Reported balance After 2024-03-18 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2024-03-18 · Disposition to issuer · Disposed 35,877 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.04 · Expires 2028-04-29	Direct	0	Reported balance After 2024-03-18 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-03-18 · Disposition to issuer · Disposed 136,094 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2028-08-08	Direct	0	Reported balance After 2024-03-18 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-03-18 · Disposition to issuer · Disposed 757,045 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-20	Direct	0	Reported balance After 2024-03-18 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-03-18 · Disposition to issuer · Disposed 449,463 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-28	Direct	0	Reported balance After 2024-03-18 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-03-18 · Disposition to issuer · Disposed 87,494 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-04-07	Direct	0	Reported balance After 2024-03-18 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-03-18 · Disposition to issuer · Disposed 15,205 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2019-06-26	Direct	0	Reported balance After 2024-03-18 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-03-18 · Disposition to issuer · Disposed 616,703 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2019-06-27	Direct	0	Reported balance After 2024-03-18 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2024-03-18 · Disposition to issuer · Disposed 71,121 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.72 · Expires 2030-02-13	Direct	0	Reported balance After 2024-03-18 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2024-03-18 · Disposition to issuer · Disposed 135,992 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.64 · Expires 2031-02-22	Direct	0	Reported balance After 2024-03-18 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2024-03-18 · Disposition to issuer · Disposed 161,850 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.97 · Expires 2032-02-16	Direct	0	Reported balance After 2024-03-18 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2024-03-18 · Disposition to issuer · Disposed 146,900 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $187.26 · Expires 2023-02-08	Direct	0	Reported balance After 2024-03-18 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2024-03-18 · Disposition to issuer · Disposed 22,800 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers.

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.

F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F6: These Options are fully vested.

F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 20, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	13,096	$161.32	$2,112,646.72	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (14) Disclosed balance after: 143,326 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · kind: Represents 33,593 shares held directly by the McGill Trust; 46,566 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F15 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $162.36 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	16,182	$161.20	$2,608,538.40	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (12) Disclosed balance after: 156,422 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · kind: Represents 46,689 shares held directly by the McGill Trust; 46,566 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F13 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.87 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	14,321	$161.32	$2,310,263.72	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (10) Disclosed balance after: 172,604 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · kind: Represents 46,689 shares held directly by the McGill Trust; 46,566 shares held directly by the Jordan Fisch Trust; 46,782 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F11 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $162.355 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 18, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	875	$161.01	$140,883.75	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (8) Disclosed balance after: 186,925 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · kind: Represents 46,689 shares held directly by the McGill Trust; 46,566 shares held directly by the Jordan Fisch Trust; 46,782 shares held directly by the Aaron Paul Trust; and 46,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F9 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.05 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 18, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	800	$161.02	$128,816.00	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (6) Disclosed balance after: 187,800 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · kind: Represents 46,689 shares held directly by the McGill Trust; 46,566 shares held directly by the Jordan Fisch Trust; 47,657 shares held directly by the Aaron Paul Trust; and 46,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F7 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.16 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 18, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	1,200	$161.14	$193,368.00	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (4) Disclosed balance after: 188,600 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · kind: Represents 46,689 shares held directly by the McGill Trust; 47,366 shares held directly by the Jordan Fisch Trust; 47,657 shares held directly by the Aaron Paul Trust; and 46,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F5 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.38 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 18, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	900	$161.01	$144,909.00	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (2) Disclosed balance after: 189,800 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · kind: Represents 47,889 shares held directly by the McGill Trust; 47,366 shares held directly by the Jordan Fisch Trust; 47,657 shares held directly by the Aaron Paul Trust; and 46,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.03 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	700	$161.00	$112,700.00	Disclosure SEC source: 0001562180-19-001684 · primarydocument.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (6) Disclosed balance after: 190,700 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · kind: Represents 47,889 shares held directly by the McGill Trust; 47,366 shares held directly by the Jordan Fisch Trust; 47,657 shares held directly by the Aaron Paul Trust; and 47,788 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	700	$161.00	$112,700.00	Disclosure SEC source: 0001562180-19-001684 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (5) Disclosed balance after: 191,400 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · kind: Represents 47,889 shares held directly by the McGill Trust; 47,366 shares held directly by the Jordan Fisch Trust; 48,357 shares held directly by the Aaron Paul Trust; and 47,788 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.00	$80,500.00	Disclosure SEC source: 0001562180-19-001684 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (4) Disclosed balance after: 192,100 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · kind: Represents 47,889 shares held directly by the McGill Trust; 48,066 shares held directly by the Jordan Fisch Trust; 48,357 shares held directly by the Aaron Paul Trust; and 47,788 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	700	$161.00	$112,700.00	Disclosure SEC source: 0001562180-19-001684 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (2) Disclosed balance after: 192,600 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · kind: Represents 48,389 shares held directly by the McGill Trust; 48,066 shares held directly by the Jordan Fisch Trust; 48,357 shares held directly by the Aaron Paul Trust; and 47,788 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	30,600	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 10 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (10) Disclosed balance after: 193,300 F10 · kind: Represents 48,389 shares held directly by the McGill Trust; 48,066 shares held directly by the Jordan Fisch Trust; 48,357 shares held directly by the Aaron Paul Trust; and 48,488 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	30,600	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (9) Disclosed balance after: 162,700 F9 · kind: Represents 48,389 shares held directly by the McGill Trust; 48,066 shares held directly by the Jordan Fisch Trust; 48,357 shares held directly by the Aaron Paul Trust; and 17,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	30,600	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (8) Disclosed balance after: 132,100 F8 · kind: Represents 48,389 shares held directly by the McGill Trust; 48,066 shares held directly by the Jordan Fisch Trust; 17,757 shares held directly by the Aaron Paul Trust; and 17,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	30,600	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (7) Disclosed balance after: 101,500 F7 · kind: Represents 48,389 shares held directly by the McGill Trust; 17,466 shares held directly by the Jordan Fisch Trust; 17,757 shares held directly by the Aaron Paul Trust; and 17,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	122,400	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (6) Disclosed balance after: 119,295 F6 · kind: Represents 119,295 shares held in the Steven M Paul Family 2018 Delaware Irrevocable Trust FBO Jann Paul of which the trustee is J.P. Morgan and for which the reporting person is an investment adviser. The reporting person disclaims Section 16 beneficial ownership of the shares held in this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.00	$80,500.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (5) Disclosed balance after: 70,900 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · kind: Represents 17,789 shares held directly by the McGill Trust; 17,466 shares held directly by the Jordan Fisch Trust; 17,757 shares held directly by the Aaron Paul Trust; and 17,888 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.00	$80,500.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (4) Disclosed balance after: 71,400 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · kind: Represents 17,789 shares held directly by the McGill Trust; 17,466 shares held directly by the Jordan Fisch Trust; 17,757 shares held directly by the Aaron Paul Trust; and 18,388 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.00	$80,500.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (3) Disclosed balance after: 71,900 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · kind: Represents 17,789 shares held directly by the McGill Trust; 17,966 shares held directly by the Jordan Fisch Trust; 17,757 shares held directly by the Aaron Paul Trust; and 18,388 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:48 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.00	$80,500.00	Disclosure SEC source: 0001562180-19-001473 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (2) Disclosed balance after: 72,400 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · kind: Represents 17,789 shares held directly by the McGill Trust; 17,966 shares held directly by the Jordan Fisch Trust; 18,257 shares held directly by the Aaron Paul Trust; and 18,388 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 19, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	200	$162.00	$32,400.00	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 10 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (15) Disclosed balance after: 72,900 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · kind: Represents 18,289 shares held directly by the McGill Trust; 17,966 shares held directly by the Jordan Fisch Trust; 18,257 shares held directly by the Aaron Paul Trust; and 18,388 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 19, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	643	$161.37	$103,760.91	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (13) Disclosed balance after: 73,100 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · kind: Represents 18,289 shares held directly by the McGill Trust; 17,966 shares held directly by the Jordan Fisch Trust; 18,257 shares held directly by the Aaron Paul Trust; and 18,588 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F14 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $162.00 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 19, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	500	$161.62	$80,812.00	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (11) Disclosed balance after: 73,743 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · kind: Represents 18,932 shares held directly by the McGill Trust; 17,966 shares held directly by the Jordan Fisch Trust; 18,257 shares held directly by the Aaron Paul Trust; and 18,588 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F12 · price: This transaction was executed in multiple trades at prices ranging from $161.28 USD to $162.00 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 19, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	200	$162.00	$32,400.00	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (10) Disclosed balance after: 74,243 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · kind: Represents 18,932 shares held directly by the McGill Trust; 18,466 shares held directly by the Jordan Fisch Trust; 18,257 shares held directly by the Aaron Paul Trust; and 18,588 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 15, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	12,388	$161.02	$1,994,715.76	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (9) Disclosed balance after: 74,443 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · kind: Represents 18,932 shares held directly by the McGill Trust; 18,466 shares held directly by the Jordan Fisch Trust; 18,457 shares held directly by the Aaron Paul Trust; and 18,588 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F4 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.21 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	12,044	$161.02	$1,939,324.88	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (7) Disclosed balance after: 86,831 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · kind: Represents 18,932 shares held directly by the McGill Trust; 18,466 shares held directly by the Jordan Fisch Trust; 18,457 shares held directly by the Aaron Paul Trust; and 30,976 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F8 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.42 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	12,510	$161.02	$2,014,360.20	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (5) Disclosed balance after: 98,875 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · kind: Represents 30,976 shares held directly by the McGill Trust; 18,466 shares held directly by the Jordan Fisch Trust; 18,457 shares held directly by the Aaron Paul Trust; and 30,976 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F6 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.29 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	12,519	$161.02	$2,015,809.38	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (3) Disclosed balance after: 111,385 F2 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · kind: Represents 30,976 shares held directly by the McGill Trust; 30,976 shares held directly by the Jordan Fisch Trust; 18,457 shares held directly by the Aaron Paul Trust; and 30,976 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F4 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.21 USD. The price reported above reflects the weighted average sale price. Read SEC document
February 01, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	241,695	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 241,695 F1 · kind: Represents 241,695 shares that, upon termination of a grantor retained annuity trust, were disbursed to the Steven M Paul Family 2018 Delaware Irrevocable Trust FBO Jann Paul of which the trustee is J.P. Morgan and for which the reporting person is an investment adviser. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
February 01, 2019 Filed Feb 20, 2019 12:55 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	241,695	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001080 · primarydocument.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,777 F1 · kind: Represents 241,695 shares that, upon termination of a grantor retained annuity trust, were disbursed to the Steven M Paul Family 2018 Delaware Irrevocable Trust FBO Jann Paul of which the trustee is J.P. Morgan and for which the reporting person is an investment adviser. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
July 26, 2018 Filed Feb 15, 2019 01:30 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	123,904	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001008 · primarydocument.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (5) Disclosed balance after: 123,904 F5 · kind: Represents 30,976 shares held directly by the McGill Trust; 30,976 shares held directly by the Jordan Fisch Trust; 30,976 shares held directly by the Aaron Paul Trust; and 30,976 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
July 26, 2018 Filed Feb 15, 2019 01:30 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	123,904	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001008 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (4) Disclosed balance after: 0 F4 · kind: Represents the aggregate 123,904 shares that the Jann Paul Irrevocable Trust transferred in four equal amounts of 30,976 to the Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Morgan McGill (the "McGill Trust"), of which the trustees are J.P. Morgan and Morgan McGill and for which the reporting person is an investment adviser; the Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Jordan Fisch (the "Fisch Trust"), of which the trustees are J.P. Morgan and Jordan Fisch and for which the reporting person is an investment adviser; the Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Aaron Paul (the "Aaron Paul Trust"), of which the trustees are J.P. Morgan and Aaron Paul and for which the reporting person is an investment adviser; and and Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Austin Paul (the "Austin Paul Trust"), of which the trustees are J.P. Morgan and Austin Paul and for which the reporting person is an investment adviser. Read SEC document
July 13, 2018 Filed Feb 15, 2019 01:30 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	121,035	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001008 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes (2)(3) Disclosed balance after: 123,904 F2 · kind: Represents 121,035 shares that, upon termination of a grantor retained annuity trust, were distributed to the Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Jann Paul (the "Jann Paul Irrevocable Trust"), of which the trustee is J.P. Morgan and for which the reporting person is an investment adviser. F3 · kind: Includes 2,869 shares that, upon termination of a grantor retained annuity trust, were previously distributed to the Jann Paul Irrevocable Trust, and which shares were inadvertently omitted from the reporting person's previously disclosed aggregate indirect beneficial ownership. The reporting person disclaims Section 16 beneficial ownership of the shares held in this trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
July 13, 2018 Filed Feb 15, 2019 01:30 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	121,035	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001008 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,472 F2 · kind: Represents 121,035 shares that, upon termination of a grantor retained annuity trust, were distributed to the Steven M. Paul Family 2018 Delaware Irrevocable Trust FBO Jann Paul (the "Jann Paul Irrevocable Trust"), of which the trustee is J.P. Morgan and for which the reporting person is an investment adviser. Read SEC document
June 20, 2018 Filed Jun 22, 2018 20:18 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $105.26	$0.00	Disclosure SEC source: 0001735276-18-000030 · edgardoc.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document
June 06, 2018 Filed Jun 8, 2018 20:03 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $154.06	$0.00	Disclosure SEC source: 0001562180-18-002929 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 6, 2019 or the day immediately prior to the 2019 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
March 07, 2018 Filed Mar 10, 2018 00:12 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	110,000	$0.00 Strike: $28.72	$0.00	Disclosure SEC source: 0001104659-18-016417 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over two years, with 1/24th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/24th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document
March 06, 2018 Filed Mar 8, 2018 21:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	58,139	$172.00	$9,999,908.00	Disclosure SEC source: 0001562180-18-001557 · primarydocument.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,712 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
June 07, 2017 Filed Jun 8, 2017 23:38 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $72.74	$0.00	Disclosure SEC source: 0001562180-17-002240 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 02, 2017 Filed Jun 6, 2017 20:58 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	11,250	$0.00 Strike: $71.99	$0.00	Disclosure SEC source: 0001553878-17-000026 · edgardoc.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document
February 08, 2017 Filed Feb 10, 2017 21:01 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	240,000	$11.83 Strike: $11.83	$2,839,200.00	Disclosure SEC source: 0001104659-17-008172 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2027-02-08 F1 · derivative.exercise_date: This stock option award was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan and will vest in 48 equal monthly installments from grant date. Read SEC document
January 31, 2017 Filed Feb 17, 2017 22:57 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	OtherCommon Stock	2,174	$3.15	$6,848.10	Disclosure SEC source: 0001562180-17-000806 · primarydocument.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,851 F1 · kind: Reporting person did not directly purchase the shares. These shares were distributed to the reporting person as an investment in a private equity fund. Read SEC document
February 01, 2010 Filed Feb 3, 2010 16:16 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionRestricted Stock Unit · Derivative	51,249	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-10-006362 · doc4.xml · derivative · entry 6 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,249 shares Expires 2010-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2010 Filed Feb 3, 2010 16:16 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	17,352	$35.20	$610,790.40	Disclosure SEC source: 0001209191-10-006362 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,897 Read SEC document
February 01, 2010 Filed Feb 3, 2010 16:16 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionCommon Stock	51,249	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006362 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 26, 2010 Filed Jan 28, 2010 23:22 UTC	ELI LILLY & Co LLY · Entity 2794	GrantRestricted Stock Unit · Derivative	82,942	$0.00	$0.00	Disclosure SEC source: 0001209191-10-005356 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,942 Underlying: Common Stock · 82,942 shares Expires 2011-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document
December 23, 2009 Filed Feb 3, 2010 17:21 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	28,854	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006401 · doc5.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 37,407 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
December 23, 2009 Filed Feb 3, 2010 17:21 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	28,854	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006401 · doc5.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document
December 22, 2009 Filed Feb 3, 2010 17:21 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	8,553	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006401 · doc5.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 8,553 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
December 22, 2009 Filed Feb 3, 2010 17:21 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	8,553	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006401 · doc5.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · EVP, Science and Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,854 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.